Literature DB >> 4359995

Clinical evaluation of indoramin, a new antihypertensive agent.

P J Lewis, C F George, C T Dollery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4359995     DOI： 10.1007/bf00644733

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Cardiovascular actions of Wy 21901, a new hypotensive and anti-arrhythmic agent.

Authors:  B J Alps; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

2.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

3.  Pharmacologic studies of indoramin in man.

Authors:  R B Royds; D J Coltart; J D Lockhart
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

4.  Alpha and beta adrenergic blockade in hypertension.

Authors:  L J Beilin; B E Juel-Jensen
Journal:  Lancet       Date:  1972-05-06       Impact factor: 79.321

5.  Intravenously administered isoproterenol sulfate dose-response curves in man.

Authors:  C F George; M E Conolly; T Fenyvesi; R Briant; C T Dollery
Journal:  Arch Intern Med       Date:  1972-09
  5 in total
  11 in total

1.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

Authors:  M G Scott; A H Deering; M T McMahon; D W Harron; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.

Authors:  C de White; R B Royds; P Turner
Journal:  Postgrad Med J       Date:  1974-12       Impact factor: 2.401

3.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

4.  Failure of ejaculation with indoramin.

Authors:  B Pentland; D A Anderson; J A Critchley
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-02

5.  Initial clinical experience with a new peripheral vasodilator, PR-G-138-Cl, in hypertensive patients.

Authors:  H P Blumental; J R Ryan; F G McMahon
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

6.  Effect of indoramin on finger blood flow in vasospastic patients.

Authors:  D L Clement
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

Review 7.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

8.  Prevention of exercise-induced asthma by indoramin.

Authors:  S Bianco; J P Griffin; P L Kamburoff; F J Prime
Journal:  Br Med J       Date:  1974-10-05

9.  The action of indoramin and other compounds on the uptake of neurotransmitters into rat cortical slices.

Authors:  R F Sugden
Journal:  Br J Pharmacol       Date:  1974-07       Impact factor: 8.739

10.  Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.

Authors:  A J Marshall; M A Kettle; D W Barritt
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.